News
PAVM
5.36
+6.14%
0.31
Weekly Report: what happened at PAVM last week (0622-0626)?
Weekly Report · 1d ago
PAVmed Shareholders Approve Plan Changes at Annual Meeting
TipRanks · 5d ago
PAVmed shareholders approve Employee Stock Purchase Plan amendments at annual meeting
PUBT · 5d ago
Lucid Diagnostics shareholders approve charter amendment raising authorized common shares to 400 million
PUBT · 5d ago
Three new option listings and seven option delistings on June 22nd
TipRanks · 06/22 13:00
Weekly Report: what happened at PAVM last week (0615-0619)?
Weekly Report · 06/22 09:55
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 06/18 21:06
Weekly Report: what happened at PAVM last week (0608-0612)?
Weekly Report · 06/15 09:56
Weekly Report: what happened at PAVM last week (0601-0605)?
Weekly Report · 06/08 09:53
Weekly Report: what happened at PAVM last week (0525-0529)?
Weekly Report · 06/01 09:56
Weekly Report: what happened at PAVM last week (0518-0522)?
Weekly Report · 05/25 09:58
Lucid Diagnostics director Dennis Matheis acquires 245,000 common shares for $245,270.00
PUBT · 05/21 20:20
Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16
TipRanks · 05/19 15:45
Weekly Report: what happened at PAVM last week (0511-0515)?
Weekly Report · 05/18 09:58
PAVmed Earnings Call: Restructuring Done, Execution Ahead
TipRanks · 05/16 00:13
PAVmed targets Varis FDA submission by end of 2026 while evaluating new assets following cap table cleanup
Seeking Alpha · 05/15 15:42
PAVmed (PAVM) Q1 2026 Earnings Transcript
NASDAQ · 05/15 15:36
PAVmed Q1 2026 Earnings Call Transcript
Benzinga · 05/15 14:11
PAVmed reports Q1 non-GAAP EPS ($1.17) vs. ($1.97) last year
TipRanks · 05/15 13:16
PAVmed Non-GAAP EPS of -$1.17 misses by $0.48, revenue of $0.02M misses by $0.08M
Seeking Alpha · 05/15 12:36
More
Webull provides a variety of real-time PAVM stock news. You can receive the latest news about Pavmed through multiple platforms. This information may help you make smarter investment decisions.
About PAVM
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.